Knowledge base
1,824 claims across 19 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,824ai alignment 395health 320internet finance 306space development 227entertainment 169grand strategy 141collective intelligence 52mechanisms 34teleological economics 30living agents 30cultural dynamics 29critical systems 24energy 23teleohumanity 18living capital 10robotics 5manufacturing 5technology 3unknown 3
AI-assisted human-authorized targeting satisfies 'no autonomous weapons' red lines while performing substantive targeting cognition because red lines defined by action type (autonomous vs. assisted) rather than decision quality (genuine human judgment vs. rubber-stamp approval) create definitional escape hatches
The Intercept's investigation reveals that OpenAI's red line against 'autonomous weapons' contains a structural loophole: the contract prohibits AI 'independently controlling lethal weapons where law or policy requires human oversight' but explicitly permits AI to generate target lists, provide trac
DoD January 2026 AI strategy structurally mandates the removal of vendor safety restrictions across all military AI contracts by creating a 180-day 'any lawful use' compliance deadline that forces AI vendors to choose between safety constraints and access to the DoD market
Secretary of Defense Hegseth's January 9, 2026 AI strategy memo contains two structural directives: (1) The Secretary of War for Acquisition and Sustainment must incorporate standard 'any lawful use' language into any DoW contract through which AI services are procured within 180 days (deadline appr
Pre-enforcement retreat is a fifth governance failure mode where mandatory AI governance with enacted requirements is deferred via legislative action before enforcement can test whether it constrains frontier AI
The EU AI Act entered force in August 2024 with staggered enforcement deadlines. Article 5 prohibited practices became enforceable February 2025 (15+ months with zero enforcement actions). GPAI transparency obligations became enforceable August 2025. In November 2025, 11 months before the high-risk
Supply chain risk designation weaponizes national security procurement law to punish AI safety constraints, as confirmed by federal court finding that the designation was designed to punish First Amendment-protected speech not to protect national security
Judge Rita Lin issued a preliminary injunction blocking the DoD supply chain risk designation of Anthropic, ruling that the designation was 'likely both contrary to law and arbitrary and capricious.' The court explicitly found that 'nothing in the statute supports the Orwellian notion that an Americ
Regulation by contract is structurally inadequate for military AI governance because bilateral procurement agreements lack the democratic accountability, institutional durability, and universal applicability required to govern AI deployment in national security contexts
Tillipman's structural critique identifies regulation by contract as fundamentally mismatched to the governance problem it's being asked to solve. Unlike statutes, contracts bind only the parties who signed them—when Anthropic is excluded from DoD contracts for maintaining safety restrictions, OpenA
Open-weight AI model release bypasses 'any lawful use' contract negotiation entirely by eliminating the vendor relationship, enabling DoD to inspect and modify internal architecture without contractual restrictions
NVIDIA's IL7 deal and Reflection AI's open-weight commitment represent a separate track from the 'any lawful use' contractual mandate: by committing to open-weight model release, DoD can inspect and modify internal architecture WITHOUT the 'any lawful use' contract negotiation. This bypasses the ven
GLP-1 anhedonia measurement gap creates monitoring blind spot for most reported psychiatric adverse effect
A comprehensive 38-study systematic review found that anhedonia data is 'ABSENT' from GLP-1 psychiatric literature despite being the most commonly reported psychiatric adverse effect in clinical practice. The review notes 'emotional blunting mentioned as potential adverse outcome but no incidence da
Semaglutide fails to slow Alzheimer's disease progression despite biomarker effects distinguishing metabolic risk reduction from disease-modifying potential in established neurodegeneration
The EVOKE and EVOKE+ Phase 3 trials enrolled 3,800 patients with confirmed Alzheimer's pathology and mild symptomatic disease, randomized to oral semaglutide 14mg vs placebo for 104 weeks. Both trials showed NO DIFFERENCE in primary endpoint (CDR-SB change) or secondary endpoint (ADCS-ADL-MCI). Crit
GLP-1 prescribing competency gap creates structural safety risk through primary care psychiatric drug misclassification
GLP-1 receptor agonists engage VTA, nucleus accumbens, insula, and prefrontal cortex to directly regulate reward pathways and reinforcement learning — making them functionally psychiatric drugs. However, they are prescribed primarily by primary care physicians for weight loss without psychiatric mon
GLP-1 metabolic monitoring protocol uses glucose-ketone ratio for therapeutic targeting
Dr. Bosworth developed a metabolic monitoring protocol for GLP-1 therapy using blood glucose divided by blood ketones (the 'Dr. Boz Ratio'). The ratio provides three operational zones: >80 indicates glucose metabolism dominance, 40-80 indicates moderate ketosis, and <40 indicates deeper therapeutic
GLP-1 biomarker improvement without clinical benefit demonstrates surrogate endpoint limitation in neurodegeneration trials
The EVOKE trials produced a striking disconnection: statistically significant 10% reduction in CSF p-tau181 at week 78, yet zero change in Clinical Dementia Rating Sum of Boxes (CDR-SB) or Activities of Daily Living (ADCS-ADL-MCI) at week 104. Trial experts agreed the biomarker magnitude was insuffi
GLP-1 metabolic screening for schizophrenia patients uses 5.4% HbA1c threshold for early-stage risk targeting, below the 5.7% prediabetes cutoff
The Psychopharmacology Institute's Q1 2026 guidance establishes a 5.4% HbA1c screening threshold for initiating GLP-1 consideration in schizophrenia patients on clozapine or olanzapine. This threshold is 0.3 percentage points below the standard 5.7% prediabetes cutoff, positioning GLP-1 as a prevent
GLP-1 psychotropic co-medication quadruples suicidal ideation risk through pharmacodynamic interaction
Pharmacovigilance analysis within a 38-study systematic review found elevated suicidal ideation odds ratios of 4.45 for patients concurrently using GLP-1 receptor agonists with antidepressants, and 4.07 for concurrent benzodiazepine users. This represents a 4-fold increase in suicidal ideation risk
GLP-1 low-dose psychiatric protocol prevents anhedonia through ketogenic diet pairing at 0.6mg weekly tirzepatide
Dr. Bosworth and Dr. Albright report no emotional blunting in approximately 100-patient cohorts using low-dose tirzepatide at 0.6mg weekly — one-quarter the standard 2.5mg starting dose — paired with ketogenic diet. The protocol includes structured resistance training and adequate protein intake (1.
GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration
Converging evidence from multiple 2025-2026 trials reveals a clear anatomical pattern in GLP-1 CNS efficacy. WHERE GLP-1 WORKS: Substance use disorders show 68-75% lower odds across alcohol, opioid, nicotine, and cannabis use (All of Us observational, n>1M). Alcohol use disorder RCT demonstrated 41%
GLP-1 receptor agonists demonstrate circuit-specific CNS effects—efficacy in reward pathways but not neurodegenerative pathways
The Gill MDD trial showing positive effects on effort-based decision-making (reward circuit function) combined with EVOKE/EVOKE-Plus Alzheimer's trial failures establishes a clear pattern: GLP-1 receptor agonists demonstrate efficacy in reward pathway disorders (major depression motivation deficits,
Psychiatry addresses GLP-1 prescribing competency through CME infrastructure rather than formal APA guidelines, creating uneven competency distribution across the prescriber population
As of Q1 2026, no formal American Psychiatric Association clinical practice guideline exists for GLP-1 receptor agonist use in psychiatric populations. Instead, the Psychopharmacology Institute — a widely used CME platform for psychiatrists — published structured clinical guidance as part of their q
Semaglutide reduces effort-cost sensitivity in major depressive disorder through reward circuit engagement, not cognitive enhancement
In a 16-week double-blind RCT (n=72), oral semaglutide 14mg significantly reduced sensitivity to effort cost in effort-based decision-making tasks (β = -1.737; P = .03) while showing no effect on executive function (adjusted Z score difference: 0.32; 95% CI: -0.92 to 1.58; p=0.60). This dissociation
CFTC event contract regulation is structural not predictive creating DCM architecture dependency
WilmerHale's April 2026 guidance establishes a critical regulatory principle: 'event contracts are not regulated based on what they predict but on how they are structured, offered, traded, cleared and intermediated.' This structural test means that CFTC jurisdiction depends on whether a platform ope
investment company act exposure not howey is the binding regulatory constraint on futarchy governed investment vehicles because beneficial ownership tests reach token holders even when the efforts of others prong fails
The Howey test asks whether a token sale is a securities transaction. The Investment Company Act asks whether the vehicle itself is a regulated investment company. These are independent statutes operating on different elements. A futarchy-governed vehicle can pass Howey — by decentralizing both anal
SEC security-based swap jurisdiction requires events directly affecting financial statements, excluding endogenous market signals like TWAP
Cleary Gottlieb's analysis identifies a three-part test for SEC jurisdiction over company-specific event contracts as security-based swaps under 15 U.S.C. § 78c(a)(68): (1) contract must meet CEA swap definition, (2) must relate to single issuer or narrow-based security index, (3) must involve 'an e
open sourcing channels are a structural prerequisite for futarchy governed investment vehicles to clear the howey efforts of others prong because gatekept curation makes the curators judgment essential to investment outcomes
The Howey test's fourth prong asks whether profits derive from the efforts of others. *SEC v. Glenn W. Turner Enterprises* (9th Cir. 1973) refined this from "any effort" to the "undeniably significant" managerial efforts that affect the failure or success of the enterprise. Futarchy decentralizes th
China's Orbital Chenguang financing through $8.4B state banking credit lines enables orbital infrastructure development without near-term commercial viability requirements, creating asymmetric capital advantage over equity-funded competitors
Orbital Chenguang secured $8.4B (57.7B yuan) in credit lines from 12 major state banks (Bank of China, Agricultural Bank of China, etc.) backed by Beijing municipal government and Zhongguancun Science Park. This financing structure is fundamentally different from equity-funded commercial programs —
Kessler-critical density is altitude-stratified with above-700km LEO already past self-sustaining cascade threshold while 550km Starlink band retains partial protection from 5-year atmospheric drag deorbit
Multiple independent simulation studies confirm that debris population above 700km continues to grow even under zero-future-launches scenarios, meaning the collision rate is high enough to sustain cascade growth independently. The sun-synchronous corridor at 780-820km is identified as the most criti
China's orbital computing strategy involves at least two parallel programs at different maturity levels — Three-Body (operational civilian/commercial) and Orbital Chenguang (pre-operational state-backed) — following China's established dual-track approach to strategic technology development
Three-Body Computing Constellation (ADA Space + Zhejiang Lab) has been operational since May 2025 with 12 satellites launched, completing a 9-month in-orbit test by February 2026. The constellation delivers 744 TOPS per satellite, 5 PFLOPS collectively, with 94% classification accuracy without groun
Page 5 of 73